ketamine has been researched along with Anankastic Personality in 19 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
Excerpt | Relevance | Reference |
---|---|---|
"The N-methyl-D-aspartate receptor antagonist ketamine has rapid onset activity in treatment-resistant depression, post-traumatic stress disorder and obsessive compulsive disorder." | 9.24 | Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. ( Anderson-Fahey, B; Glue, P; Gray, A; Harland, S; Le Nedelec, M; McNaughton, N; Medlicott, NJ; Neehoff, S, 2017) |
"We previously reported the rapid and robust clinical effects of ketamine versus saline infusions in a proof-of-concept crossover trial in unmedicated adults with obsessive-compulsive disorder (OCD)." | 9.20 | In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: Proof of concept. ( Flood, P; Hunter, L; Kegeles, LS; Levinson, A; Mao, X; Milak, MS; Moore, H; Ogden, RT; Rodriguez, CI; Shungu, DC; Simpson, HB; Vermes, D; Xie, S, 2015) |
"Ketamine has shown some promise in treating OCD." | 5.56 | Clinical utility of repeated intravenous ketamine treatment for resistant obsessive-compulsive disorder. ( Arumugham, SS; Balachander, S; Jaisoorya, TS; Janardhanan, CN; Reddy, YCJ; Sharma, LP; Thamby, A, 2020) |
"Ketamine is a non-competitive N-methyl-D-aspartate receptor antagonist that is Food and Drug Administration-approved in the United States for anesthesia due to its sedative effects with low risk of severe respiratory depression." | 5.39 | Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder. ( Bloch, MH; Corlett, PR; Grunschel, BD; Niciu, MJ; Pittenger, C, 2013) |
"Ketamine is a potent noncompetitive antagonist of the N-methyl-D-aspartate glutamate receptor." | 5.38 | Effects of ketamine in treatment-refractory obsessive-compulsive disorder. ( Bhagwagar, Z; Billingslea, E; Bloch, MH; Krystal, JH; Landeros-Weisenberger, A; Leckman, JF; Panza, KE; Pittenger, C; Sanacora, G; Wasylink, S, 2012) |
"The N-methyl-D-aspartate receptor antagonist ketamine has rapid onset activity in treatment-resistant depression, post-traumatic stress disorder and obsessive compulsive disorder." | 5.24 | Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. ( Anderson-Fahey, B; Glue, P; Gray, A; Harland, S; Le Nedelec, M; McNaughton, N; Medlicott, NJ; Neehoff, S, 2017) |
"We previously reported the rapid and robust clinical effects of ketamine versus saline infusions in a proof-of-concept crossover trial in unmedicated adults with obsessive-compulsive disorder (OCD)." | 5.20 | In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: Proof of concept. ( Flood, P; Hunter, L; Kegeles, LS; Levinson, A; Mao, X; Milak, MS; Moore, H; Ogden, RT; Rodriguez, CI; Shungu, DC; Simpson, HB; Vermes, D; Xie, S, 2015) |
"Ketamine has shown some promise in treating OCD." | 1.56 | Clinical utility of repeated intravenous ketamine treatment for resistant obsessive-compulsive disorder. ( Arumugham, SS; Balachander, S; Jaisoorya, TS; Janardhanan, CN; Reddy, YCJ; Sharma, LP; Thamby, A, 2020) |
"Ketamine is a non-competitive N-methyl-D-aspartate receptor antagonist that is Food and Drug Administration-approved in the United States for anesthesia due to its sedative effects with low risk of severe respiratory depression." | 1.39 | Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder. ( Bloch, MH; Corlett, PR; Grunschel, BD; Niciu, MJ; Pittenger, C, 2013) |
"Ketamine is a potent noncompetitive antagonist of the N-methyl-D-aspartate glutamate receptor." | 1.38 | Effects of ketamine in treatment-refractory obsessive-compulsive disorder. ( Bhagwagar, Z; Billingslea, E; Bloch, MH; Krystal, JH; Landeros-Weisenberger, A; Leckman, JF; Panza, KE; Pittenger, C; Sanacora, G; Wasylink, S, 2012) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 13 (68.42) | 24.3611 |
2020's | 6 (31.58) | 2.80 |
Authors | Studies |
---|---|
Davis, GL | 1 |
Minerva, AR | 1 |
Lario, A | 1 |
Simmler, LD | 1 |
Rodriguez, CI | 7 |
Gunaydin, LA | 1 |
Bottemanne, H | 1 |
Arnould, A | 1 |
Najar, A | 1 |
Delaigue, F | 1 |
Serresse, L | 1 |
Joly, L | 1 |
Mouchabac, S | 1 |
Thompson, SL | 1 |
Welch, AC | 1 |
Iourinets, J | 1 |
Dulawa, SC | 1 |
Peyrovian, B | 1 |
McIntyre, RS | 1 |
Phan, L | 1 |
Lui, LMW | 1 |
Gill, H | 1 |
Majeed, A | 1 |
Chen-Li, D | 1 |
Nasri, F | 1 |
Rosenblat, JD | 1 |
Sharma, LP | 1 |
Thamby, A | 1 |
Balachander, S | 1 |
Janardhanan, CN | 1 |
Jaisoorya, TS | 1 |
Arumugham, SS | 1 |
Reddy, YCJ | 1 |
Veraart, JKE | 1 |
Kamphuis, J | 1 |
Schlegel, M | 1 |
Schoevers, RA | 1 |
Glue, P | 1 |
Medlicott, NJ | 1 |
Harland, S | 1 |
Neehoff, S | 1 |
Anderson-Fahey, B | 1 |
Le Nedelec, M | 1 |
Gray, A | 1 |
McNaughton, N | 1 |
Lapidus, KAB | 1 |
Zwerling, J | 3 |
Levinson, A | 4 |
Mahnke, A | 1 |
Steinman, SA | 2 |
Kalanthroff, E | 1 |
Simpson, HB | 6 |
M Koran, L | 1 |
Aboujaoude, E | 1 |
Tosta, CL | 1 |
Silote, GP | 1 |
Fracalossi, MP | 1 |
Sartim, AG | 1 |
Andreatini, R | 1 |
Joca, SRL | 1 |
Beijamini, V | 1 |
Niciu, MJ | 1 |
Grunschel, BD | 1 |
Corlett, PR | 1 |
Pittenger, C | 3 |
Bloch, MH | 3 |
Kegeles, LS | 3 |
Feng, T | 1 |
Marcus, SM | 1 |
Vermes, D | 3 |
Flood, P | 3 |
Wink, LK | 1 |
O'Melia, AM | 1 |
Shaffer, RC | 1 |
Pedapati, E | 1 |
Friedmann, K | 1 |
Schaefer, T | 1 |
Erickson, CA | 1 |
Ogden, RT | 1 |
Mao, X | 1 |
Milak, MS | 1 |
Xie, S | 1 |
Hunter, L | 1 |
Moore, H | 1 |
Shungu, DC | 1 |
Wheaton, M | 1 |
Sonnenfeld, D | 1 |
Galfalvy, H | 1 |
Adams, TG | 1 |
Wasylink, S | 1 |
Landeros-Weisenberger, A | 1 |
Panza, KE | 1 |
Billingslea, E | 1 |
Leckman, JF | 1 |
Krystal, JH | 1 |
Bhagwagar, Z | 1 |
Sanacora, G | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Ketamine Infusion for Social Anxiety Disorder[NCT02083926] | Early Phase 1 | 18 participants (Actual) | Interventional | 2015-01-02 | Completed | ||
Ketamine Infusion for Obsessive-Compulsive Disorder[NCT01349231] | Phase 2 | 10 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
Understanding the Glutamate System in Adults With Obsessive-Compulsive Disorder With N-methyl-D Aspartate Antagonist Ketamine[NCT01100255] | Phase 2 | 15 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)[NCT02422290] | Phase 1/Phase 2 | 5 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
Extending Ketamine's Effects in Obsessive-Compulsive Disorder (OCD) With Exposure and Response Prevention (EX/RP)[NCT02062658] | Phase 2 | 10 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
Open -Label Trial on the Effects of Memantine in Adults With Obsessive-Compulsive Disorder After a Single Ketamine Infusion[NCT00956085] | Phase 2 | 12 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Clinician-administered scale for the assessment of fear and avoidance found in social phobia (SAD); it has 24 items divided into 2 subscales, 13 for performance anxiety, and 11 for social situations each rated from 0 to 3 (0=none,1=mild,2=moderate,3=definite). The sum scores for Fear and Avoidance results in an overall score (max 144 points). There are 4 clinician subscales: fear of social interaction, fear of performance, avoidance of social interaction and avoidance of performance 0 to 30= SAD is unlikely 30 to 60=SAD is probable 60 to 90=SADis very probable >90= SAD highly probable (NCT02083926)
Timeframe: Day 1 (1+28)
Intervention | score on a scale (Mean) |
---|---|
Ketamine Infusion on Day 0 or Day 28 | 66.1 |
Saline Infusion on Day 0 or Day 28 | 86.1 |
"Instrument that tries to measure anxiety, that is believed to range across a continuum of values and cannot easily be directly measured.We used a straight horizontal line of 100 mm in length. The ends were defined as the extreme limits of the parameter to be measured (anxiety); oriented from the left (no anxiety) to the right (worst anxiety ever felt). The patient marks on the line the point that they feel represents their perception of their current state.The VAS score is determined by measuring in millimeters from the left hand end of the line to the point that the patient marks.~We examined Visual Analog Scale (VAS) for anxiety symptoms at screening, 1 hour prior to infusion, 1, 2 and 3 hours after infusion, 1, 2, 3, 5, 7, 10, and 14 days following a single ketamine/saline infusion." (NCT02083926)
Timeframe: Day 1 (1+28)
Intervention | units on a scale (Mean) |
---|---|
Ketamine Infusion on Day 0 or Day 28 | 12.1 |
Saline Infusion on Day 0 or Day 28 | 19.6 |
We will examine change from baseline in the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) ratings of OCD severity at 1 day following infusion. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) assesses obsessive and compulsive symptom severity. Obsessions are rated on a scale from 0-20 and compulsions are rated on a scale of 0-20, for a total scale of 0-40. Scores on the obsessions scale and scores on the compulsions scale are summed to obtain the total score. The higher the score, the more severe the OCD. (NCT01349231)
Timeframe: Baseline and 1 day after ketamine infusion
Intervention | units on a scale (Mean) |
---|---|
Ketamine | -2.7 |
We will examine change from baseline in the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) ratings of OCD severity at 2 days following infusion. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) assesses obsessive and compulsive symptom severity. Obsessions are rated on a scale from 0-20 and compulsions are rated on a scale of 0-20, for a total scale of 0-40. Scores on the obsessions scale and scores on the compulsions scale are summed to obtain the total score. The higher the score, the more severe the OCD. (NCT01349231)
Timeframe: Baseline and 2 days following infusion
Intervention | units on a scale (Mean) |
---|---|
Ketamine | -3.6 |
We will examine change from baseline in the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) ratings of OCD severity at 3 days following infusion. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) assesses obsessive and compulsive symptom severity. Obsessions are rated on a scale from 0-20 and compulsions are rated on a scale of 0-20, for a total scale of 0-40. Scores on the obsessions scale and scores on the compulsions scale are summed to obtain the total score. The higher the score, the more severe the OCD. (NCT01349231)
Timeframe: Baseline and 3 days following infusion
Intervention | units on a scale (Mean) |
---|---|
Ketamine | -2.9 |
We will examine change from baseline in Hamilton Rating Scale for Depression (HRDS) ratings of depression severity at day 1-3 following a single ketamine infusion. The HRDS assesses severity of, and change in, depressive symptoms. The HRDS is a 21 item scale with scores ranging from 0-66. The higher the score, the more severe the depression. (NCT01349231)
Timeframe: Baseline, Day 1, Day 2, and Day 3
Intervention | units on a scale (Mean) | ||
---|---|---|---|
HRDS change from Baseline to Day 1 | HRDS change from Baseline to Day 2 | HRDS change from Baseline to Day 3 | |
Ketamine | -6.57 | -7.29 | -5.14 |
Patients given YBOCS (Yale Brown Obsessive-Compulsive Scale), a gold standard measure of obsessions and compulsions. For the YBOCS the minimum units are 0 and Maximum units on the total scale are 40. The higher the number on the YBOCS, the more severe the symptoms. Response was defined as at least a 35% reduction on the YBOCS. (NCT01100255)
Timeframe: 1 week
Intervention | participants (Number) |
---|---|
Saline Infusion | 0 |
Ketamine Infusion | 5 |
The CY-BOCS is a semi-structured measure of OCD severity with excellent inter-rater reliability, internal consistency, and test-retest reliability. It is validated in those starting at age 7 and used in studies up to age 20. The CYBOCS differs from the adult YBOCS only in its use of simpler language. The CY-BOCS consists of 10 items which are summed up to derive the total CY-BOCS score. The total score ranges from 0-40 with higher scores indicating greater severity of OCD symptoms. (NCT02422290)
Timeframe: Screening, Baseline, Day 7, Day 17, 3-Month; Baseline and Day 14 pre-specified to be reported
Intervention | score on a scale (Mean) | |
---|---|---|
CY-BOCS Baseline | CY-BOCS Day 14 | |
Ketamine Treatment Group | 29.00 | 26.20 |
The CGI-S is a clinician rated 7-point rating scale for the severity of a participant's illness relative to the clinician's experience of working with this particular population. The score ranges from 1-7 with higher scores indicating greater illness severity. (NCT02422290)
Timeframe: Screening, Baseline, Day 7, Day 17, 3-Month; Baseline and Day 14 pre-specified to be reported
Intervention | score on a scale (Mean) | |
---|---|---|
CGI-S Baseline | CGI-S Day 14 | |
Ketamine Treatment Group | 5.80 | 5.00 |
"The OCD-VAS is a one-item unipolar scale to assess OCD symptoms over a rapid time frame (No obsessions to Constant obsessions). The scale ranges from 0-10 with higher scores indicating higher presence of obsessions." (NCT02422290)
Timeframe: Screening, Baseline, Day 1-14, 3-Month; Baseline and Day 14 pre-specified to be reported
Intervention | score on a scale (Mean) | |
---|---|---|
OCD-VAS Baseline | OCD-VAS Day 14 | |
Ketamine Treatment Group | 5.00 | 5.00 |
"The Y-BOCCS is self-report scale which assesses OCD symptoms on a 5-point likert scale (None to Extreme). It consists of 10 items which are summed up to derive the total Y-BOCCS score. The total score ranges from 0-40 with higher scores indicating higher prevalence of OCD symptoms." (NCT02422290)
Timeframe: Screening, Baseline, Day 1-14, 3-Month; Baseline and Day 14 pre-specified to be reported
Intervention | score on a scale (Mean) | |
---|---|---|
Y-BOCCS Baseline | Y-BOCCS Day 14 | |
Ketamine Treatment Group | 18.25 | 16.50 |
Patients given YBOCS (Yale Brown Obsessive-Compulsive Scale), a gold standard measure of obsessions and compulsions. For the YBOCS the minimum units are 0 and Maximum units on the total scale are 40. The higher the number on the YBOCS, the more severe the symptoms. Response was defined as at least a 35% reduction on the YBOCS. (NCT02062658)
Timeframe: 2 weeks
Intervention | participants (Number) |
---|---|
Ketamine, Exposure & Response Prevention | 5 |
Patients given YBOCS (Yale Brown Obsessive-Compulsive Scale), a gold standard measure of obsessions and compulsions. For the YBOCS the minimum units are 0 and Maximum units on the total scale are 40. The higher the number on the YBOCS, the more severe the symptoms. Response was defined as at least a 35% reduction on the YBOCS. (NCT00956085)
Timeframe: Baseline and 6 weeks
Intervention | Participants (Count of Participants) |
---|---|
Memantine | 4 |
1 review available for ketamine and Anankastic Personality
Article | Year |
---|---|
Promising Treatments for Obsessive-Compulsive Disorder: A Call for Additional Research.
Topics: Caffeine; Cognitive Behavioral Therapy; Combined Modality Therapy; Humans; Ketamine; Memantine; Obse | 2018 |
6 trials available for ketamine and Anankastic Personality
Article | Year |
---|---|
Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Anxiety Disorders; Depression; Depressiv | 2017 |
Challenges in Testing Intranasal Ketamine in Obsessive-Compulsive Disorder.
Topics: Administration, Intranasal; Adolescent; Adult; Drug Administration Schedule; Excitatory Amino Acid A | 2017 |
Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Humans; K | 2013 |
Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Humans; K | 2013 |
Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Humans; K | 2013 |
Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Humans; K | 2013 |
In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: Proof of concept.
Topics: Adult; Cross-Over Studies; Excitatory Amino Acid Antagonists; Female; gamma-Aminobutyric Acid; Gluta | 2015 |
Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? an open-label trial.
Topics: Administration, Intravenous; Adolescent; Adult; Cognitive Behavioral Therapy; Combined Modality Ther | 2016 |
Open-Label trial on the effects of memantine in adults with obsessive-compulsive disorder after a single ketamine infusion.
Topics: Administration, Intravenous; Adult; Diagnostic and Statistical Manual of Mental Disorders; Drug Subs | 2016 |
12 other studies available for ketamine and Anankastic Personality
Article | Year |
---|---|
Ketamine increases activity of a fronto-striatal projection that regulates compulsive behavior in SAPAP3 knockout mice.
Topics: Animals; Compulsive Behavior; Corpus Striatum; Disease Models, Animal; Female; Grooming; Humans; Ket | 2021 |
[Combination of ketamine and esketamine with Exposure and Response Prevention (ERP) therapy for Obsessive-Compulsive Disorder].
Topics: Extinction, Psychological; Fear; Humans; Implosive Therapy; Ketamine; Obsessive-Compulsive Disorder; | 2023 |
Ketamine induces immediate and delayed alterations of OCD-like behavior.
Topics: Animals; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Female; Ketamine; Mice | 2020 |
Registered clinical trials investigating ketamine for psychiatric disorders.
Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine; Obsessive-Compulsive Disorder; | 2020 |
Clinical utility of repeated intravenous ketamine treatment for resistant obsessive-compulsive disorder.
Topics: Adult; Humans; Infusions, Intravenous; Ketamine; Obsessive-Compulsive Disorder; Selective Serotonin | 2020 |
Oral S-ketamine effective after deep brain stimulation in severe treatment-resistant depression and extensive comorbidities.
Topics: Administration, Oral; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Clozapine; D | 2021 |
S-ketamine reduces marble burying behaviour: Involvement of ventromedial orbitofrontal cortex and AMPA receptors.
Topics: Animals; Drug Evaluation, Preclinical; Ketamine; Male; Mice; Motor Activity; Obsessive-Compulsive Di | 2019 |
Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder.
Topics: Adult; Anxiety; Depressive Disorder, Major; Female; Humans; Ketamine; Middle Aged; Obsessive-Compuls | 2013 |
Intranasal ketamine treatment in an adult with autism spectrum disorder.
Topics: Administration, Intranasal; Adult; Anorexia Nervosa; Child Development Disorders, Pervasive; Depress | 2014 |
Intranasal Ketamine and Cognitive-Behavioral Therapy for Treatment-Refractory Obsessive-Compulsive Disorder.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Cognitive Behavioral Therapy; Combined Mod | 2017 |
Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder.
Topics: Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Humans; Infusions, Intravenous; Keta | 2011 |
Effects of ketamine in treatment-refractory obsessive-compulsive disorder.
Topics: Adolescent; Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Female; Hum | 2012 |